Published in Women's Health Weekly, December 15th, 1997
In pre-clinical evaluation, Matritech's scientists demonstrated that the antibody strongly reacts with a nuclear matrix protein (NMP 179) found in cervical carcinoma, definitively staining both malignant and pre-malignant cervical cancer cells. Initial findings were submitted as an abstract to the American Society for Colposcopy and Cervical Pathology by Dr. Ellen Sheets, a researcher at Brigham and Women's Hospital in Boston, Massachusetts, and collaborator in the study.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.